10:00 am Chair’s Opening Remarks
Looking at Novel Targets & the Clinical Development for Solid Tumors
10:00 am Nectin-4, An Ideal ADC Target, or Maybe Not?
Synopsis
• Providing a description of Nectin-4 biology and its relevance to oncology
• Reviewing challenges to be addressed for an ADC
• Sharing key learnings and relevance for other targets
10:30 am Development & Clinical Translation of ELU001, a Targeted Ultra- Small Topoisomerase 1 C’Dot Conjugate for the Treatment of Solid Tumors
Synopsis
• C’Dots are ultra-small, 6 nM particles that can be functionalized with up to 80 payloads and targeting moieties
• Due to their size and neutral properties C’Dot Drug Conjugates (CDCs) localize in and penetrate rapidly into solid tumors including difficult to access tumors in the brain and pancreas
• ELU001 is an exatecan conjugated CDC that is targeted to Folate Receptor Alpha overexpressing tumors via folic acid moieties on its surface
11:00 am SOT102, A Novel CLDN18.2-Targeting Antibody-Drug Conjugate With Strong Therapeutic Potential in Solid Tumors
Synopsis
• SOT102 is based on a novel proprietary CLDN18.2 specific monoclonal antibody, conjugated to PNU-159682
• Evaluate how SOT102 demonstrated strong antitumor activity in mouse PDX models of gastric, pancreatic and other solid tumors, including those with low target expression
• Gain an update on a Phase 1/2 study in patients with gastric and pancreatic cancer that is planned to start in early 2022
11:30 am Virtual Speed Networking
Synopsis
This session is the ideal opportunity to get face-to-face time with many of the brightest minds working in the ADC Targets field and establish meaningful business relationships to pursue for the rest of the conference.
12:30 pm Session Reserved for Eisai
1:00 pm Quantitative Proteomics Approaches for ADC Target Characterization
Synopsis
• Discuss DIA-MS peptide level quantification for epitope and isoform precision
• Explore how to quantify cell surface protein dynamics using pulsed SILAC labeling
• Examine the profiling of protein drug interactions (PDIs) using IP-MS
1:30 pm Panel Discussion: When Defining Target Criteria, Do You Explore Clean Target or Dirty Targets? Then Solid Tumor Vs Cancer Targets
2:00 pm Lunch & Networking
3:00 pm Session Reserved for AstraZeneca
3:30 pm Target Identification at the Intersection of Indication & Payload
Synopsis
• Highlight the multifactorial aspect of target identification
• Discuss the significance of comprehensive understanding of antigen expression as function of stage of tumorigenesis
• Illustrate the enhanced value of pairing payload mechanism and indication
4:00 pm Identification of Novel pHLA Targets for Solid Tumor Targeting with ADCs
Synopsis
• Discuss the advantages of intracellular targets (pHLAs) versus viral, neoantigens or conventional cell surface antigens
• Uncover strategies to find the most prevalent and immunogenic pHLA targets in tumors from CPI responders
• Review the selection of ADCs targeting pHLA targets to avoid off-tumor, on-target toxicities in normal tissues